The Kable

The Kable

Share this post

The Kable
The Kable
💉 GSK’s RSV vaccine hits main goal in trials; Novartis hits a brick wall in court; Sanofi says sayonara to Japanese manufacturing
Copy link
Facebook
Email
Notes
More
Friday Kable

💉 GSK’s RSV vaccine hits main goal in trials; Novartis hits a brick wall in court; Sanofi says sayonara to Japanese manufacturing

#194 | TRIPping over Covid extensions

Vinod's avatar
Vinod
Oct 14, 2022
∙ Paid
1

Share this post

The Kable
The Kable
💉 GSK’s RSV vaccine hits main goal in trials; Novartis hits a brick wall in court; Sanofi says sayonara to Japanese manufacturing
Copy link
Facebook
Email
Notes
More
Share

Hello and welcome to The Kable one last time this week, before we usher you into the weekend.

In news today, Novartis does to Ireland what it is doing to Switzerland: laying off people. 400 of them.

Maybe some of these redundant Irish workers could move to South Korea, where CDMO Samsung Biologics has started operations at the world's largest single bio-m…

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 The Kable
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More